Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Investment Securities (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Gains from Investment Securities data on record, last reported at $11.0 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $11.0 million; the TTM value through Dec 2025 reached -$5.0 million, changed N/A, while the annual FY2025 figure was -$5.0 million, 171.43% down from the prior year.
  • Gains from Investment Securities reached $11.0 million in Q4 2025 per RCUS's latest filing, up from -$1.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $24.5 million in Q2 2021 and bottomed at -$25.2 million in Q3 2021.
  • Average Gains from Investment Securities over 5 years is $660000.0, with a median of -$63000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: soared 18629.77% in 2021, then crashed 1433.33% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $17.8 million in 2021, then tumbled by 94.93% to $900000.0 in 2022, then plummeted by 1433.33% to -$12.0 million in 2023, then soared by 91.67% to -$1.0 million in 2024, then skyrocketed by 1200.0% to $11.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $11.0 million in Q4 2025, -$1.0 million in Q3 2024, and -$10.0 million in Q2 2024.